Baird Medical Expands Interventional Thyroidology Across the U.S.

Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) is ramping up its presence in the United States with significant advancements in interventional thyroidology. On February 25, 2026, the company announced promising clinical developments that align with its strategy to broaden patient access to innovative, minimally invasive therapies. This initiative reflects Baird Medical’s commitment to expanding its global footprint in the healthcare sector.

The company is reinforcing its market position, particularly in the western United States. Samer Nakhle, M.D., FACE, ECNU, Medical Director of Palm Medical Group in Las Vegas, Nevada, recently employed Baird Medical’s microwave ablation technology for benign thyroid applications. His efforts are integral to the wider adoption of these advanced treatments across various clinical settings.

In a similar vein, Sophie Dream, M.D., MPH, FACS, an Associate Professor and Chief of the Section of Endocrine Surgery at the University of Alabama at Birmingham, is leading initiatives that further this national momentum. She has utilized Baird Medical’s platforms to effectively treat benign thyroid conditions, empowering medical professionals to embrace cutting-edge, tissue-sparing interventions.

Mark Saxton, US CEO of Baird Medical, emphasized the importance of integrating their systems into both leading academic institutions and private practices. “These recent milestones validate our commercial roadmap and ensure more physicians have the tools necessary to elevate patient care,” he stated.

Commitment to Advanced Treatments

Baird Medical is recognized for its dedication to advancing minimally invasive diagnostics and treatments. The company specializes in surgical robotic systems and innovative instruments designed to enhance patient outcomes through precise technology. Baird Medical’s solutions have been implemented in over 30 prestigious hospitals and clinics throughout the United States, including renowned facilities such as the Mayo Clinic and Columbia University Medical Center.

The company is also a leader in the Chinese market for thyroid microwave ablation devices and consumables. Its products are gradually establishing a commercial presence in more than 20 countries globally, reflecting a strategic approach to expanding its reach.

Baird Medical’s commitment to improving healthcare extends beyond surgical assistance; it aims to develop intelligent systems that guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical adheres to rigorous safety and efficacy standards, ensuring that its products meet the highest quality benchmarks.

Looking Ahead

The future of Baird Medical appears promising, driven by its ongoing innovation and strategic partnerships with leading academic institutions. While the company aims to solidify its expansion efforts in both the United States and China, the path forward comes with inherent risks. These include potential regulatory changes, economic fluctuations, and the competitive landscape of the medical device industry.

The company’s recent progress highlights its proactive approach to enhancing patient care through advanced technology and collaboration. As Baird Medical continues to innovate, it seeks to empower healthcare professionals with the tools necessary to provide effective and minimally invasive treatments, ultimately transforming patient experiences.

For further information, contact Eric Huang, PR Liaison at Baird Medical Investment Holdings Ltd., via phone at +1 (888) 508-6228 or email at [email protected].

Readers are encouraged to stay informed about Baird Medical’s developments as it navigates the complexities of the healthcare landscape while striving to improve patient outcomes globally.